Moderna, Merck mRNA vaccine lowers melanoma return odds

A melanoma patient leaves the operating room with the visible tumour gone, but not necessarily the uncertainty. Top-line results released last week show that an mRNA cancer immunotherapy from Moderna and Merck lowered the odds of surgically removed melanoma spreading or coming back.

The treatment is described as a neoantigen cancer immunotherapy. The source does not provide the trial’s patient count, the size of the reduction, or the follow-up period, and no detailed results are included here. That leaves the finding promising but incomplete: doctors still need to see the full data before judging how broadly the treatment should be used.

The result is also testing the language around mRNA. Reports on the top-line results seemed to avoid calling the treatment an mRNA vaccine. Ryan Sullivan, a Mass General Brigham melanoma physician and immunologist who has worked with Moderna, said the result could help people think of “vaccine” as something useful against cancer rather than as a taboo word.

That shift matters because mRNA technology has faced a post-pandemic backlash, with Moderna especially caught in the political and public reaction. The same agency that helped fund the company’s Covid-19 vaccine through Operation Warp Speed later removed more than half a billion dollars in grants supporting mRNA vaccine development projects.

So what changes, concretely? For people whose melanoma has been surgically removed, the treatment could offer another way to reduce the risk of the cancer returning or spreading—if the full study confirms the top-line finding. For the field, it gives mRNA a potential role beyond infectious disease, while the missing trial details remain the boundary between an encouraging signal and a treatment doctors can rely on.